FI3607962T3 - Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon - Google Patents

Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon

Info

Publication number
FI3607962T3
FI3607962T3 FIEP19197866.7T FI19197866T FI3607962T3 FI 3607962 T3 FI3607962 T3 FI 3607962T3 FI 19197866 T FI19197866 T FI 19197866T FI 3607962 T3 FI3607962 T3 FI 3607962T3
Authority
FI
Finland
Prior art keywords
composition
use according
angiotensin
catecholamine
vasopressin
Prior art date
Application number
FIEP19197866.7T
Other languages
English (en)
Finnish (fi)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3607962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressionally Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Application granted granted Critical
Publication of FI3607962T3 publication Critical patent/FI3607962T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP19197866.7T 2013-12-18 2014-12-18 Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon FI3607962T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
FI3607962T3 true FI3607962T3 (fi) 2025-11-24

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19197866.7T FI3607962T3 (fi) 2013-12-18 2014-12-18 Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR102399383B1 (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (1) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (1) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (1) LT2986308T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (1) PL2986308T3 (enExample)
PT (1) PT2986308T (enExample)
RS (1) RS59804B1 (enExample)
SI (1) SI2986308T1 (enExample)
SM (1) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
AU2014364528C1 (en) 2013-12-18 2021-01-07 The George Washington University, A Congressional Chartered Not-For-Profit Corporation Angiotensin ll alone or in combination for the treatment of hypotension
TWI754225B (zh) * 2014-07-08 2022-02-01 美商拉荷亞製藥公司 治療低血壓之方法
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
EP3400000B1 (en) * 2016-01-07 2023-12-06 La Jolla Pharma, LLC Methods for administering angiotensin ii
CA3010788A1 (en) * 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
TW201927331A (zh) * 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法
WO2023244552A1 (en) * 2022-06-15 2023-12-21 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
EP4633658A1 (en) * 2022-12-12 2025-10-22 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
CA2448051A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
ATE507243T1 (de) 2005-09-29 2011-05-15 Fibrogen Inc Verfahren zur senkung des blutdrucks
EP1971358A4 (en) * 2005-12-30 2010-05-26 Florey Howard Inst Methods of Treatment
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
WO2010062896A1 (en) 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2988770A4 (en) 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
AU2014364528C1 (en) 2013-12-18 2021-01-07 The George Washington University, A Congressional Chartered Not-For-Profit Corporation Angiotensin ll alone or in combination for the treatment of hypotension
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
TWI754225B (zh) 2014-07-08 2022-02-01 美商拉荷亞製藥公司 治療低血壓之方法
CA3010788A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
EP3400000B1 (en) 2016-01-07 2023-12-06 La Jolla Pharma, LLC Methods for administering angiotensin ii
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
TW201927331A (zh) 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法

Also Published As

Publication number Publication date
KR102399383B1 (ko) 2022-05-19
CN112546197A (zh) 2021-03-26
US20180193407A1 (en) 2018-07-12
US20220047669A1 (en) 2022-02-17
CN106061493A (zh) 2016-10-26
HRP20200009T1 (hr) 2020-03-20
DK2986308T3 (en) 2020-01-27
ES2771749T3 (es) 2020-07-07
AU2024219851A1 (en) 2024-10-10
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
US10493124B2 (en) 2019-12-03
JP2017501154A (ja) 2017-01-12
US9220745B2 (en) 2015-12-29
US20160129072A1 (en) 2016-05-12
MX2020011190A (es) 2020-11-13
IL246162B (en) 2020-03-31
US20190070250A1 (en) 2019-03-07
US10765722B2 (en) 2020-09-08
RS59804B1 (sr) 2020-02-28
US20150164980A1 (en) 2015-06-18
JP2022137224A (ja) 2022-09-21
IL246162A0 (en) 2016-07-31
WO2015095535A9 (en) 2016-07-14
AU2014364528C1 (en) 2021-01-07
AU2014364528A1 (en) 2016-06-30
KR20230051721A (ko) 2023-04-18
US20190328827A1 (en) 2019-10-31
MX2016008108A (es) 2017-03-09
DK3607962T3 (da) 2025-11-17
US20230226141A1 (en) 2023-07-20
KR20220028125A (ko) 2022-03-08
PT2986308T (pt) 2020-01-21
WO2015095535A1 (en) 2015-06-25
EP3607962B1 (en) 2025-08-13
US10028995B2 (en) 2018-07-24
AU2014364528A9 (en) 2016-07-28
JP7175506B2 (ja) 2022-11-21
EP2986308B1 (en) 2019-10-16
JP6824739B2 (ja) 2021-02-03
EA037823B1 (ru) 2021-05-25
LT2986308T (lt) 2020-03-25
US11559559B2 (en) 2023-01-24
EP2986308A4 (en) 2017-01-11
JP2025114753A (ja) 2025-08-05
AU2014364528B2 (en) 2020-08-27
PL2986308T3 (pl) 2020-05-18
CN111920939A (zh) 2020-11-13
MX380968B (es) 2025-03-12
BR112016013961A2 (pt) 2017-10-10
EP2986308A1 (en) 2016-02-24
SMT202000018T1 (it) 2020-03-13
SI2986308T1 (sl) 2020-03-31
KR20240154702A (ko) 2024-10-25
HUE047062T2 (hu) 2020-04-28
CN119700926A (zh) 2025-03-28
CY1122604T1 (el) 2021-03-12
CA2933601A1 (en) 2015-06-25
EP3607962A1 (en) 2020-02-12
NZ721089A (en) 2022-10-28
JP2019214610A (ja) 2019-12-19
AU2020277230A1 (en) 2020-12-24
EA201691258A1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
FI3607962T3 (fi) Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
FI4374873T3 (fi) Aine käytettäväksi silmäsairauksien hoidossa tai ehkäisyssä
MX365094B (es) Metodo para inhibir flt3 cinasa fosforilada constitutivamente activa.
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
MX389893B (es) Sistemas de bombeo de fluido medico y dispositivos y metodos relacionados.
FI3593817T3 (fi) Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
PH12015502275B1 (en) Therapuetic uses of empagliflozin
WO2012002687A3 (en) Methods for treating bipolar disorder
WO2009094194A3 (en) Diagnostic and therapeutic uses of gelsolin in renal failure
WO2011091225A3 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
CA2914620C (en) Heterocyclic derivatives and use thereof
RU2019138024A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9c, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
JP2013504519A5 (enExample)
MX336477B (es) Derivado de aminoacido.
MX2012001107A (es) Derivado de amida.
ZA202203563B (en) Pediatric suspension formulation
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA201100243A1 (ru) Композиции для лечения розацеи
RU2016111957A (ru) Офтальмическая композиция для цвиттерионных мягких контактных линз
PH12014500251A1 (en) N-hetero-ring-substituted amide derivative